Last reviewed · How we verify
CUG252
At a glance
| Generic name | CUG252 |
|---|---|
| Sponsor | Cugene Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus (PHASE1)
- A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CUG252 CI brief — competitive landscape report
- CUG252 updates RSS · CI watch RSS
- Cugene Inc. portfolio CI